Research
Mixed
Antiviral treatment for mild chronic hepatitis C is not cost-effective for patients aged 65 or over with genotype 1, as it leads to fewer QALYs gained.
For patients aged 65 or older with genotype 1 mild hepatitis C, antiviral treatment is generally not recommended as cost-effective because it may not improve quality-adjusted life years and costs significantly more than the threshold for value. In these cases, regular monitoring (liver biopsy) is likely the more prudent clinical strategy.
GoodRefutesHIGH confidence
For patients with genotype 1 aged 65, providing interferon-alfa and ribavirin for mild disease led to fewer QALYs gained, and a mean cost per QALY of £53,017.
Why this rating
Based on the same RCT and Markov model.
Source
The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review
Emma Loveman et al. · Health Technology Assessment · 2011
DOI 10.3310/hta15020
rct · n=98Cited 299×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →